50
https://pubmed.ncbi.nlm.nih.gov/38116449
Scientists have developed a new fully chemical, site-specific strategy for producing bispecific antibodies (BisAbs) using AJICAP second-generation technology and haloketone chemistry, which shows promising stability, activity, and intact antigen binding.